NASDAQ:DVAX - Dynavax Technologies Stock Price, Forecast & News

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) announced its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. The biopharmaceutical company earned $10.58 million during the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative net margin of 519.95% and a negative return on equity of 399.60%. The business's revenue was up 624.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.65) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

5 brokerages have issued 1-year target prices for Dynavax Technologies' shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Dynavax Technologies' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 203.6% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

News coverage about DVAX stock has trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Dynavax Technologies earned a news impact score of 0.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the immediate future. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Chicago Capital LLC (4.77%), Senvest Management LLC (4.76%), Bain Capital Public Equity Management II LLC (4.24%), State Street Corp (4.11%), UBS Asset Management Americas Inc. (2.08%) and Blair William & Co. IL (2.01%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Senvest Management LLC, Point72 Asset Management L.P., Chicago Capital LLC, FMR LLC, DekaBank Deutsche Girozentrale, Rhenman & Partners Asset Management AB, Bank of America Corp DE and Gables Capital Management Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Bain Capital Public Equity Management II LLC, Oxford Asset Management LLP, Rafferty Asset Management LLC, California Public Employees Retirement System, Alpine Global Management LLC, Blair William & Co. IL and Bank of New York Mellon Corp. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $5.05.

Dynavax Technologies has a market capitalization of $423.49 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]